Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Abstract Background Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficac...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	BMC 2024-04-01
Sraith:	The Journal of Headache and Pain
Ábhair:	Rimegepant Migraine Acute treatment China Clinical trial
Rochtain ar líne:	https://doi.org/10.1186/s10194-024-01731-4
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!